Responses
Clinical/translational cancer immunotherapy
Original research
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
